Phio Pharmaceuticals Corp (PHIO)

[sabaidii2]

RXI's problem is its finances. While I'd prefer the looming reverse split to not occur, it's really just a bookkeeping event.

No, the major negative is the planned $15 million dilution. With RXI's current market cap of about $15 million, it would be ruinous for shareholders. Granted, the dilution will occur over a 30-month duration, but still.

However, all is not lost: according to the last CC (Nov 12, 2017) "the Company expects to have available cash until the third quarter of 2018". In other words, there is still ample time (I figure 3-4 months) for that fabled upfront $ deal to be done before any dilutions actually begin.